The license represents an extension of the existing license of all the GVK Bio Target and Drug databases. The GVK Bio databases contain over 3.2 million compounds manually curated from patents and journals and represent over 7 million quantitative SAR data points. MBT database has over 13,000 drug and drug like compounds, their routes of metabolism, toxic indications and the numerical values of the measures of toxicity. The data has been manually curated from over 35,000 individual references.
Sreeni Devidas, vice president of business development at GVK BIO, said: “The MBT provides easily accessible information on known toxic effects of over 13,000 compounds from the literature, which will be made available to researchers in AstraZeneca.”